Showing results (91-100 of 190) with videos related to
Sort By:
Pageof 19
The Journal of the Acoustical Society of America|December 31, 2024
Profile analysis in listeners with normal and elevated audiometric thresholds: Behavioral and modeling resultsDaniel R Guest, David A Cameron, Douglas M Schwarz, et al.British Journal of Cancer|November 6, 2025
Annual versus less frequent mammographic surveillance in people with breast cancer aged 50 years and older in the UK (Mammo-50): cost-effectiveness and budget impact analysisPaola Cocco, Chris Bojke, Claire Hulme, et al.Advances in Therapy|April 8, 2025
A Cost-Effectiveness Analysis of Abemaciclib in Combination with Adjuvant Endocrine Therapy for HR+, HER2-, Node-Positive, High-Risk Early Breast CancerAlison Davie, Sory Traoré, Waleed Badreldin, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 19, 2005
Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute trial AB01Ruth E Langley, James Carmichael, Alison L Jones, et al.Breast Cancer Research : BCR|April 11, 2013
Is TIMP-1 immunoreactivity alone or in combination with other markers a predictor of benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial?Alison F Munro, Annette Bartels, Eva Balslev, et al.Journal of the National Cancer Institute|February 10, 2018
Associations Between Serum Bone Biomarkers in Early Breast Cancer and Development of Bone Metastasis: Results From the AZURE (BIG01/04) TrialJanet Brown, Emma Rathbone, Samantha Hinsley, et al.Breast Cancer Research and Treatment|June 1, 2022
Breast cancer incidence and survival in Scotland by socio-economic deprivation and tumour subtypeInes Mesa-Eguiagaray, Sarah H Wild, Sheila M Bird, et al.International Journal of Population Data Science|February 1, 2023
Variation in hospital cost trajectories at the end of life by age, multimorbidity and cancer typeKatharina Diernberger, Xhyljeta Luta, Joanna Bowden, et al.The American Journal of Surgical Pathology|May 18, 2005
Columnar cell lesions of the breast: the missing link in breast cancer progression? A morphological and molecular analysisPeter T Simpson, Theo Gale, Jorge S Reis-Filho, et al.Endocrine-Related Cancer|December 13, 2006
Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer modelsBarbara Kuske, Catherine Naughton, Kate Moore, et al.Pageof 19